-
公开(公告)号：EP2970161B8
公开(公告)日：2018-10-17
申请号：EP14717540.0
申请日：2014-03-07
发明人： SUI, Zhihua , CAI, Chaozhong , ZHANG, Xuqing
IPC分类号： C07D275/00 , C07D333/32 , C07D417/04 , C07D417/12 , A61K31/381 , A61K31/425 , A61P3/04 , A61P3/10
CPC分类号： C07D417/12 , C07D275/00 , C07D275/02 , C07D275/03 , C07D333/16 , C07D333/32 , C07D409/04 , C07D417/04
摘要： Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.
-
公开(公告)号：EP1383750A2
公开(公告)日：2004-01-28
申请号：EP02710010.6
申请日：2002-01-15
发明人： JIMENEZ MAYORGA, Juan Miguel , BACH TANA, Jordi , ONTORIA ONTORIA, Jesus Maria , NAVARRO ROMERO, Eloisa
IPC分类号： C07D275/00
CPC分类号： C07D213/40 , C07C275/28 , C07C275/40 , C07C275/42 , C07C311/47 , C07C317/42 , C07C2601/14 , C07D213/75 , C07D213/79 , C07D213/81 , C07D213/82 , C07D295/192 , C07D295/205 , C07D295/26 , C07D333/20 , C07D333/36 , C07D471/04 , C07D495/04
摘要： Novel antagonists of α4β1 integrin and/or α4β7 integrin of the general Formula (I): wherein R1, R2, R5, L1, L2, Rb, W and Z are as defined in any one of claims 1 to 13, A represents -CH- or a nitrogen atom, and p is from 0 to 4.
-
公开(公告)号：EP1781673A1
公开(公告)日：2007-05-09
申请号：EP05771781.1
申请日：2005-08-16
申请人： AstraZeneca AB
发明人： AQUILA, Brian AstraZeneca R & D Boston , BLOCK, Michael, Howard AstraZeneca R & D Boston , DAVIES, Audrey AstraZeneca R & D Boston , EZHUTHACHAN, Jayachandran AstraZeneca R & D Boston , PONTZ, Timothy AstraZeneca R & D Boston , RUSSELL, Daniel, John AstraZeneca R & D Boston , THEOCLITOU, Marie-Elena AstraZeneca R & D Boston , ZHENG, XiaoLan AstraZeneca R & D Boston
IPC分类号： C07D513/04 , C07D498/04 , A61K31/519 , A61P35/00 , C07D275/00 , C07D239/00 , C07D261/00
CPC分类号： C07D513/04
摘要： This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
-
4.发明公开
公开(公告)号：EP1042305A1
公开(公告)日：2000-10-11
申请号：EP98964221.0
申请日：1998-12-22
申请人： Bayer Corporation
发明人： MILLER, Scott , OSTERHOUT, Martin , DUMAS, Jacques , KHIRE, Uday , LOWINGER, Timothy, Bruno , RIEDL, Bernd , SCOTT, William, J. , SMITH, Roger, A. , WOOD, Jill, E. , GUNN, David , HATOUM-MOKDAD, Holia , RODRIGUEZ, Mareli , SIBLEY, Robert , WANG, Ming , TURNER, Tiffany , BRENNAN, Catherine
IPC分类号： C07D273/00 , C07D275/00 , A61K31/17
CPC分类号： C07D207/27 , A61K31/17 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/425 , A61K31/428 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4436 , A61K31/4439 , A61K31/535 , A61K31/5375 , C07C205/11 , C07C205/22 , C07C205/37 , C07C205/38 , C07C205/57 , C07C205/58 , C07C275/30 , C07C275/34 , C07C275/36 , C07C275/40 , C07C275/42 , C07C309/88 , C07C311/48 , C07C317/42 , C07D207/26 , C07D207/404 , C07D209/76 , C07D209/86 , C07D209/88 , C07D213/40 , C07D213/53 , C07D213/68 , C07D213/70 , C07D231/08 , C07D233/22 , C07D233/70 , C07D263/58 , C07D277/68 , C07D295/185 , C07D307/20 , C07D333/20 , C07D409/12 , Y02A50/411
摘要： This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
-
5.发明公开GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES 有权GPR120-AGONISTEN ZUR BEHANDLUNG VON TYP-II-DIABETES
公开(公告)号：EP2970161A1
公开(公告)日：2016-01-20
申请号：EP14717540.0
申请日：2014-03-07
发明人： SUI, Zhihua , CAI, Chaozhong , ZHANG, Xuqing
IPC分类号： C07D275/00 , C07D333/32 , C07D417/04 , C07D417/12 , A61K31/381 , A61K31/425 , A61P3/04 , A61P3/10
CPC分类号： C07D417/12 , C07D275/00 , C07D275/02 , C07D275/03 , C07D333/16 , C07D333/32 , C07D409/04 , C07D417/04
摘要： Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.
摘要翻译： 公开了用于治疗受GPR120受体调节影响的病症的化合物，组合物和方法。 这样的化合物由式（I）和式（II）表示如下：其中Y，R 1，G和Q在本文中定义; 并且其中R11，R21，R41，RB1和G1在本文中定义。
-
公开(公告)号：EP2699557A4
公开(公告)日：2014-09-17
申请号：EP12774356
申请日：2012-04-20
发明人： HAYDON DAVID JOHN , CZAPLEWSKI LLOYD GEORGE , STOKES NEIL ROBERT , DAVIES DAVID , COLLINS IAN , PALMER JAMES T , MITCHELL JEFFREY PETER , PITT GARY ROBERT WILLIAM , OFFERMANN DANIEL
IPC分类号： C07D261/02 , A61K31/166 , A61K31/4245 , A61P31/04 , C07D233/54 , C07D263/02 , C07D271/06 , C07D275/00 , C07D277/00 , C07D285/00
CPC分类号： A61K31/5377 , A61K31/166 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/496 , A61K31/506 , C07D263/32 , C07D271/06 , C07D277/24 , C07D277/30 , C07D285/08 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D417/12 , C07D513/04
-
7.发明公开Novel pyrimidine derivatives and their use in perfume compositions 有权Ne en en en en en en en en en en en en en en en en en en en en en en
公开(公告)号：EP2644688A2
公开(公告)日：2013-10-02
申请号：EP12175170.5
申请日：2012-07-05
发明人： BELKO, Robert P , JONES, Paul D , LEVORSE, Anthony T. , MONTELEONE, Michael G , NARULA, Anubhav P.S. , SCHIET, Franc T
IPC分类号： C11B9/00 , A61Q13/00 , A61L9/02 , C07D231/00 , C07D233/00 , C07D235/00 , C07D239/00 , C07D239/74 , C07D241/00 , C07D241/36 , C07D261/00 , C07D263/00 , C07D265/04 , C07D265/28 , C07D275/00 , C07D277/00 , C07D279/02 , C07D279/04 , C11D3/50
CPC分类号： C11B9/0092 , A61K8/49 , A61K8/4953 , A61Q13/00 , C07D239/74 , C07D241/36 , C07D241/38 , C07D265/04 , C07D265/28 , C07D279/02 , C07D279/04 , C11B9/0096 , C11D3/50
摘要： The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula:
wherein m and n are integers that when m is 0, n is 1; when m is 1, n is 0 or 1; or when m is 2, n is 0;
wherein (CH)T" and (CH) n are each independently optionally substituted with a substituent selected from the group consisting of methyl and ethyl;
wherein X is selected from the group consisting of N, 0, and S; and
wherein R 1 and R z each independently represent H or a hydrocarbon group, or R 1 and R Z together represent a fused ring or a ring system,
with the proviso that when R 1 is H, R 2 is not H.摘要翻译： 本发明涉及新颖的嘧啶衍生物及其在香料组合物中的用途。 本发明的新型嘧啶衍生物由下式表示：其中m和n是当m为0时n为1的整数; 当m为1时，n为0或1; 或当m为2时，n为0; 其中（CH）T“和（CH）n各自独立地任选被选自甲基和乙基的取代基取代;其中X选自N，O和S;并且其中R 1和 R z各自独立地表示H或烃基，或R 1和R Z一起表示稠环或环系，条件是当R 1为H时，R 2不为H.
-
8.发明公开ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTION OF CANCER 审中-公开SELECTED者浓缩嘧啶酮的治疗和预防癌症对映体和应用
公开(公告)号：EP1781674A1
公开(公告)日：2007-05-09
申请号：EP05771880.1
申请日：2005-08-16
申请人： AstraZeneca AB
发明人： AQUILA, Brian, AstraZeneca R & D Boston , BLOCK, Michael Howard, AstraZeneca R & D Boston , DAVIES, Audrey, AstraZeneca R & D Boston , EZHUTHACHAN, J., AstraZeneca R & D Boston , PONTZ, Timothy, AstraZeneca R & D Boston , RUSSELL, Daniel John, AstraZeneca R & D Boston , THEOCLITOU, Marie-Elena, AstraZeneca R & D Boston , ZHENG, XiaoLan, AstraZeneca R & D Boston
IPC分类号： C07D513/04 , C07D498/04 , A61K31/519 , A61P35/00 , C07D275/00 , C07D239/00 , C07D261/00
CPC分类号： C07D498/04 , C07D513/04
摘要： This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
-
9.发明授权
公开(公告)号：EP1042305B1
公开(公告)日：2005-06-08
申请号：EP98964221.0
申请日：1998-12-22
发明人： MILLER, Scott , OSTERHOUT, Martin , DUMAS, Jacques , KHIRE, Uday , LOWINGER, Timothy, Bruno , RIEDL, Bernd , SCOTT, William, J. , SMITH, Roger, A. , WOOD, Jill, E. , GUNN, David , HATOUM-MOKDAD, Holia , RODRIGUEZ, Mareli , SIBLEY, Robert , WANG, Ming , TURNER, Tiffany , BRENNAN, Catherine
IPC分类号： C07D273/00 , C07D275/00 , A61K31/17 , C07D333/20 , C07D233/70 , C07D213/70 , C07D209/88 , C07C317/42 , C07C275/36 , C07C205/57 , A61K31/44 , A61K31/535 , A61K31/425 , A61K31/40 , C07D207/26 , C07D207/40 , C07D213/53 , C07D231/08 , C07D277/68 , C07D209/76 , C07D213/68 , C07D233/22 , C07D307/20 , C07C275/34 , C07C311/48
CPC分类号： C07D207/27 , A61K31/17 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/425 , A61K31/428 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4436 , A61K31/4439 , A61K31/535 , A61K31/5375 , C07C205/11 , C07C205/22 , C07C205/37 , C07C205/38 , C07C205/57 , C07C205/58 , C07C275/30 , C07C275/34 , C07C275/36 , C07C275/40 , C07C275/42 , C07C309/88 , C07C311/48 , C07C317/42 , C07D207/26 , C07D207/404 , C07D209/76 , C07D209/86 , C07D209/88 , C07D213/40 , C07D213/53 , C07D213/68 , C07D213/70 , C07D231/08 , C07D233/22 , C07D233/70 , C07D263/58 , C07D277/68 , C07D295/185 , C07D307/20 , C07D333/20 , C07D409/12 , Y02A50/411
摘要： This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
-
公开(公告)号：EP2644688B1
公开(公告)日：2017-11-08
申请号：EP12175170.5
申请日：2012-07-05
发明人： Belko, Robert P , Jones, Paul D , Levorse, Anthony T. , Monteleone, Michael G , Narula, Anubhav P.S. , Schiet, Franc T
IPC分类号： C11B9/00 , A61Q13/00 , A61L9/02 , C07D231/00 , C07D233/00 , C07D235/00 , C07D239/00 , C07D239/74 , C07D241/00 , C07D241/36 , C07D261/00 , C07D263/00 , C07D265/04 , C07D265/28 , C07D275/00 , C07D277/00 , C07D279/02 , C07D279/04 , C11D3/50 , A61K8/49 , C07D241/38
CPC分类号： C11B9/0092 , A61K8/49 , A61K8/4953 , A61Q13/00 , C07D239/74 , C07D241/36 , C07D241/38 , C07D265/04 , C07D265/28 , C07D279/02 , C07D279/04 , C11B9/0096 , C11D3/50
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.016 秒)
